Penumbra PEN Embolization and Other — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Penumbra in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Penumbra’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about Penumbra's embolization and other — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Penumbra's embolization and other — revenue?
- Penumbra (PEN) reported embolization and other — revenue of $113.94M in Q4 2025.
- How has Penumbra's embolization and other — revenue changed year-over-year?
- Penumbra's embolization and other — revenue increased by 20.2% year-over-year, from $94.79M to $113.94M.
- What is the long-term trend for Penumbra's embolization and other — revenue?
- Over 4 years (2021 to 2025), Penumbra's embolization and other — revenue has grown at a 10.1% compound annual growth rate (CAGR), from $309.82M to $455.75M.
- What does embolization and other — revenue mean?
- Total revenue generated from the sale of embolization medical devices and related secondary products.
- How do you interpret embolization and other — revenue?
- An increase indicates successful market penetration or expanded clinical adoption of the company's embolization technologies, while a decrease may signal competitive pressure or shifts in physician treatment preferences.
- How does embolization and other — revenue compare across companies?
- Comparable to specialized vascular intervention or interventional radiology product line revenues reported by medical device peers.